Cardiovascular and hemodynamic effects of glucagon-like peptide-1

Adam G. Goodwill, Kieren J. Mather, Abass M. Conteh, Daniel J. Sassoon, Jillian N. Noblet, Johnathan D. Tune

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of GLP-1 based therapies to drive myocardial substrate selection, enhance cardiac performance and regulate heart rate, blood pressure and vascular tone. These studies have produced consistent and reproducible results amongst numerous laboratories. However, there are obvious disparities in findings obtained in small animal models versus those of higher mammals. This species dependent discrepancy calls to question, the translational value of individual findings. Moreover, few studies of GLP-1 mediated cardiovascular action have been performed in the presence of a pre-existing comorbidities (e.g. obesity/diabetes) which limits interpretation of the effectiveness of incretin-based therapies in the setting of disease. This review addresses cardiovascular and hemodynamic potential of GLP-1 based therapies with attention to species specific effects as well as the interaction between therapies and disease.

Original languageEnglish (US)
Pages (from-to)209-217
Number of pages9
JournalReviews in Endocrine and Metabolic Disorders
Volume15
Issue number3
DOIs
StatePublished - Sep 2014

Fingerprint

Glucagon-Like Peptide 1
Hemodynamics
Incretins
Therapeutics
Blood Vessels
Comorbidity
Mammals
Animal Models
Obesity
Heart Rate
Hormones
Blood Pressure
Research

Keywords

  • Cardiovascular
  • GLP
  • Glucagon Like Peptide
  • Incretin

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Cardiovascular and hemodynamic effects of glucagon-like peptide-1. / Goodwill, Adam G.; Mather, Kieren J.; Conteh, Abass M.; Sassoon, Daniel J.; Noblet, Jillian N.; Tune, Johnathan D.

In: Reviews in Endocrine and Metabolic Disorders, Vol. 15, No. 3, 09.2014, p. 209-217.

Research output: Contribution to journalReview article

Goodwill, Adam G. ; Mather, Kieren J. ; Conteh, Abass M. ; Sassoon, Daniel J. ; Noblet, Jillian N. ; Tune, Johnathan D. / Cardiovascular and hemodynamic effects of glucagon-like peptide-1. In: Reviews in Endocrine and Metabolic Disorders. 2014 ; Vol. 15, No. 3. pp. 209-217.
@article{fd7c34505eec4eb4a7df4fb8f5c6e8e4,
title = "Cardiovascular and hemodynamic effects of glucagon-like peptide-1",
abstract = "Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of GLP-1 based therapies to drive myocardial substrate selection, enhance cardiac performance and regulate heart rate, blood pressure and vascular tone. These studies have produced consistent and reproducible results amongst numerous laboratories. However, there are obvious disparities in findings obtained in small animal models versus those of higher mammals. This species dependent discrepancy calls to question, the translational value of individual findings. Moreover, few studies of GLP-1 mediated cardiovascular action have been performed in the presence of a pre-existing comorbidities (e.g. obesity/diabetes) which limits interpretation of the effectiveness of incretin-based therapies in the setting of disease. This review addresses cardiovascular and hemodynamic potential of GLP-1 based therapies with attention to species specific effects as well as the interaction between therapies and disease.",
keywords = "Cardiovascular, GLP, Glucagon Like Peptide, Incretin",
author = "Goodwill, {Adam G.} and Mather, {Kieren J.} and Conteh, {Abass M.} and Sassoon, {Daniel J.} and Noblet, {Jillian N.} and Tune, {Johnathan D.}",
year = "2014",
month = "9",
doi = "10.1007/s11154-014-9290-z",
language = "English (US)",
volume = "15",
pages = "209--217",
journal = "Reviews in Endocrine and Metabolic Disorders",
issn = "1389-9155",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Cardiovascular and hemodynamic effects of glucagon-like peptide-1

AU - Goodwill, Adam G.

AU - Mather, Kieren J.

AU - Conteh, Abass M.

AU - Sassoon, Daniel J.

AU - Noblet, Jillian N.

AU - Tune, Johnathan D.

PY - 2014/9

Y1 - 2014/9

N2 - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of GLP-1 based therapies to drive myocardial substrate selection, enhance cardiac performance and regulate heart rate, blood pressure and vascular tone. These studies have produced consistent and reproducible results amongst numerous laboratories. However, there are obvious disparities in findings obtained in small animal models versus those of higher mammals. This species dependent discrepancy calls to question, the translational value of individual findings. Moreover, few studies of GLP-1 mediated cardiovascular action have been performed in the presence of a pre-existing comorbidities (e.g. obesity/diabetes) which limits interpretation of the effectiveness of incretin-based therapies in the setting of disease. This review addresses cardiovascular and hemodynamic potential of GLP-1 based therapies with attention to species specific effects as well as the interaction between therapies and disease.

AB - Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to have hemodynamic and cardioprotective capacity in addition to its better characterized glucoregulatory actions. Because of this, emerging research has focused on the ability of GLP-1 based therapies to drive myocardial substrate selection, enhance cardiac performance and regulate heart rate, blood pressure and vascular tone. These studies have produced consistent and reproducible results amongst numerous laboratories. However, there are obvious disparities in findings obtained in small animal models versus those of higher mammals. This species dependent discrepancy calls to question, the translational value of individual findings. Moreover, few studies of GLP-1 mediated cardiovascular action have been performed in the presence of a pre-existing comorbidities (e.g. obesity/diabetes) which limits interpretation of the effectiveness of incretin-based therapies in the setting of disease. This review addresses cardiovascular and hemodynamic potential of GLP-1 based therapies with attention to species specific effects as well as the interaction between therapies and disease.

KW - Cardiovascular

KW - GLP

KW - Glucagon Like Peptide

KW - Incretin

UR - http://www.scopus.com/inward/record.url?scp=84906215707&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906215707&partnerID=8YFLogxK

U2 - 10.1007/s11154-014-9290-z

DO - 10.1007/s11154-014-9290-z

M3 - Review article

C2 - 24881624

AN - SCOPUS:84906215707

VL - 15

SP - 209

EP - 217

JO - Reviews in Endocrine and Metabolic Disorders

JF - Reviews in Endocrine and Metabolic Disorders

SN - 1389-9155

IS - 3

ER -